Clinical Implication of BRAF Mutation in Thyroid Cancer.
10.16956/kjes.2014.14.3.131
- Author:
A Ram HONG
1
;
Young Joo PARK
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. yjparkmd@snu.ac.kr
- Publication Type:Review
- Keywords:
Thyroid cancer;
BRAF mutation
- MeSH:
Diagnosis;
Mortality;
Prevalence;
Prognosis;
Recurrence;
Thyroid Neoplasms*;
Thyroid Nodule
- From:Korean Journal of Endocrine Surgery
2014;14(3):131-137
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The BRAF(V600E) mutation is the most common genetic alteration and presents in 40~80% of all papillary thyroid cancer (PTC), showing the highest prevalence in the Korean population, close to 80%. Previous studies published in the past 10 years showed a significant correlation between BRAF(V600E) mutation and poor prognostic outcomes of PTC, including recurrence and mortality. Therefore, its clinical application for the diagnosis of thyroid nodule or for decisions regarding the management policy by prediction of the prognosis of thyroid cancer has been proposed. However, some recent studies have reported conflict results, and there appear to be growing concerns regard to the cost-benefit of tests for detection of the BRAF(V600E) mutation. In this paper, we reviewed previous studies regarding the BRAF(V600E) mutation and attempted to evaluate the clinical implication of the BRAF(V600E) mutation in clinical practice.
